Testing deuruxolitinib for severe hair loss in Japanese adults
Part of Skin clinical trials.
This study tests whether a new drug called deuruxolitinib can help regrow hair in people with alopecia areata (an autoimmune condition causing patchy hair loss). The drug works by blocking certain immune signals that attack hair follicles.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old
- You have alopecia areata (patchy hair loss) diagnosed by a doctor
- Your hair loss has been ongoing for at least 6 months
- Your hair loss severity meets a specific threshold (SALT score of 50+, meaning significant scalp involvement)
- You have not taken immune-suppressing medications or JAK inhibitors in the past 4 months
- You do not have hepatitis B, hepatitis C, HIV, or active tuberculosis
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational oral medication (deuruxolitinib) for adolescents with severe alopecia areata (hair loss). It aims to see if it can help hair regrow safely.
This trial tests an oral medication called NXC-736 for people with moderate to severe alopecia areata. It aims to see if the drug is safe and can help regrow hair.
This study tests an oral tablet called upadacitinib for people with severe alopecia areata who have lost at least half of their scalp hair. It aims to see if the drug can safely help hair regrow.
This study tests an investigational drug to see if it can help people with severe alopecia areata, a condition that causes hair loss. It may help regrow hair.
This Phase 2 study tests ruxolitinib to see if it safely helps regrow hair in people whose alopecia areata is linked to APECED (a rare immune condition). You may qualify if you have significant scalp hair loss for at least 6 months and haven’t had regrowth with other treatments.
This study tests a pill called baricitinib (a JAK inhibitor) to see if it can stop rapid hair loss and help hair regrow in people with recent, active alopecia areata. It focuses on those who have been shedding hair for less than three months, so it might stop the process earlier than usual.
Hear when a new Alopecia Areata trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.